Barclays
SABS icon

Barclays’s SAB Biotherapeutics SABS Stock Holding History

Barclays’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140K Buy
35,902
+35,406
+7,138% +$132K ﹤0.01% 3896
2026
Q1 		$1.9K Buy
+496
New +$1.98K ﹤0.01% 4857
2024
Q4 		– Sell
-10
Closed -$27 – 5450
2024
Q3 		$27 Buy
+10
New +$28 ﹤0.01% 5225
2023
Q2 		– Sell
-5
Closed -$24 – 5015
2023
Q1 		$24 Buy
+5
New +$32 ﹤0.01% 5024

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's SABS Position: Q2 2026 in Review

Barclays increased its SAB Biotherapeutics (SABS) stake by 7,138% in Q2 2026, buying an estimated $132K and bringing the position to 35,902 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #3896.

Barclays first reported a position in SABS in Q1 2023 and has held it in 4 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Barclays held 35,902 shares of SAB Biotherapeutics worth $140K as of Q2 2026.
  • Barclays bought 35,406 SAB Biotherapeutics shares in Q2 2026, an estimated $132K.
  • SAB Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3896 holding.
  • Barclays first reported a position in SAB Biotherapeutics in Q1 2023 and has held it in 4 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.